Mackenzie Financial’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.28M Sell
16,327
-52,999
-76% -$3.61M ﹤0.01% 1146
2026
Q1
$4.48M Buy
69,326
+11,703
+20% +$825K 0.01% 697
2025
Q4
$3.89M Buy
57,623
+22,292
+63% +$1.5M ﹤0.01% 699
2025
Q3
$2.59M Sell
35,331
-83,095
-70% -$5.52M ﹤0.01% 766
2025
Q2
$6.16M Buy
118,426
+32,817
+38% +$1.87M 0.01% 567
2025
Q1
$5.46M Buy
85,609
+68,213
+392% +$3.96M 0.01% 562
2024
Q4
$832K Sell
17,396
-1,442
-8% -$73.9K ﹤0.01% 985
2024
Q3
$1.08M Buy
18,838
+4,059
+27% +$233K ﹤0.01% 849
2024
Q2
$774K Buy
14,779
+4,393
+42% +$193K ﹤0.01% 912
2024
Q1
$423K Buy
10,386
+163
+2% +$6.11K ﹤0.01% 1061
2023
Q4
$378K Hold
10,223
﹤0.01% 1078
2023
Q3
$385K Hold
10,223
﹤0.01% 1074
2023
Q2
$377K Sell
10,223
-2,520
-20% -$86K ﹤0.01% 1103
2023
Q1
$487K Sell
12,743
-606
-5% -$28.4K ﹤0.01% 1034
2022
Q4
$760K Buy
13,349
+1,987
+17% +$102K ﹤0.01% 817
2022
Q3
$449K Sell
11,362
-50,894
-82% -$2.25M ﹤0.01% 965
2022
Q2
$2.74M Sell
62,256
-14,604
-19% -$632K ﹤0.01% 647
2022
Q1
$3.06M Sell
76,860
-3,719
-5% -$132K ﹤0.01% 674
2021
Q4
$3.24M Sell
80,579
-510
-0.6% -$19K ﹤0.01% 660
2021
Q3
$3.3M Buy
81,089
+54,652
+207% +$2.28M ﹤0.01% 647
2021
Q2
$1.2M Buy
26,437
+4,770
+22% +$211K ﹤0.01% 820
2021
Q1
$903K Buy
+21,667
New +$989K ﹤0.01% 831
2020
Q4
Sell
-17,120
Closed -$450K 1064
2020
Q3
$450K Sell
17,120
-10,822
-39% -$301K ﹤0.01% 804
2020
Q2
$749K Sell
27,942
-14,076
-33% -$318K ﹤0.01% 729
2020
Q1
$756K Buy
42,018
+30,208
+256% +$573K ﹤0.01% 716
2019
Q4
$209K Buy
+11,810
New +$205K ﹤0.01% 1035
2019
Q3
Sell
-16,820
Closed -$289K 1043
2019
Q2
$289K Hold
16,820
﹤0.01% 968
2019
Q1
$271K Buy
+16,820
New +$273K ﹤0.01% 1125

Other funds holding HALO

Mackenzie Financial's HALO Position: Q2 2026 in Review

Mackenzie Financial reduced its Halozyme (HALO) stake by 76% in Q2 2026, selling an estimated $3.61M and leaving 16,327 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1146.

Mackenzie Financial first reported a position in HALO in Q1 2019 and has held it in 28 quarters since. The position peaked at $6.16M in Q2 2025. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Mackenzie Financial held 16,327 shares of Halozyme worth $1.28M as of Q2 2026.
  • Mackenzie Financial sold 52,999 Halozyme shares in Q2 2026, an estimated $3.61M.
  • Halozyme made up ﹤0.01% of Mackenzie Financial's portfolio in Q2 2026, its #1146 holding.
  • Mackenzie Financial first reported a position in Halozyme in Q1 2019 and has held it in 28 quarters since.
  • Mackenzie Financial's Halozyme position peaked at $6.16M in Q2 2025.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.